Nerlynx

Active Ingredient(s): Neratinib Maleate
FDA Approved: * July 17, 2017
Pharm Company: * PUMA BIOTECH
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Nerlynx Overview

Neratinib (HKI-272)[1] is a tyrosine kinase inhibitor anticancer drug.[2][3] Like lapatinib and afatinib, it is a dual inhibitor of the human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases.[4] It inhibits them by covalently binding with a cysteine side chain in those proteins.[5] Neratinib has an IC50 of 59 nM against HER2 and shows weak inhibition against KDR and Scr with IC50 values of 0.8 µM and 1.4 µM, respectively. In BT474 cells, ...

Read more Nerlynx Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Neratinib

Recent Nerlynx Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Neratinib Maleate
  • Tablet: 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Nerlynx: (1 result)

Sorted by National Drug Code
  • 70437-240 Nerlynx 48.31 mg Oral Tablet by Puma Biotechnology, Inc.

Other drugs which contain Neratinib Maleate or a similar ingredient: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 19 November 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.